USP10 and dysplasia: Loss of USP10 was seen in 124 out of 194 (63.9%) small intestinal adenocarcinoma samples and correlated with a higher pT stage (P = 0.044), lymphatic invasion (P = 0.033), and the absence of sporadic adenoma (P = 0.024) and peritumoral dysplasia (P = 0.019), suggesting that loss of USP10 and p14ARF can be used as prognostic markers in small intestinal adenocarcinoma80.